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Case Report
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Volume expansion in the presence of elevated
aldosterone availability is a hallmark of normal
pregnancy. Intravascular volume depletion charac-
terizes severe pregnancy-associated disease conditions
such as intra-uterine growth retardation, chronic
hypertension or pre-eclampsia [1]. Two hypotheses
have been forwarded to explain volume depletion in
pregnancy: the ﬁrst hypothesis charges inappropriate
sensing of vascular ‘overﬁlling’, resulting in an
increased transendothelial loss of ﬂuid to the extra-
vascular compartment. In contrast, the second hypo-
thesis focuses on vascular ‘underﬁlling’ due to
inappropriately low aldosterone levels. The second
hypothesis is based on the assumption that a compen-
satory increase in the circulating ﬂuid volume is
required in normal pregnancy to support fetal substrate
delivery. According to the second concept, maternal
blood pressure increases due to counter-regulatory
mechanisms when placental blood supply is reduced
[2]. In support of the ‘underﬁlling’ hypothesis are
observations that a compromised volume status before
pregnancy or a reduced ability to retain sodium by
pregnant women predicts a complicated pregnancy
outcome. The relevance of intravascular volume
expansion during normal pregnancy is also supported
by the clinical observation that further reduction of
ﬂuids by prescribing either diuretics or salt restriction
does not prevent or improve the course of the disease
[3]. On the contrary, acute volume expansion in overt
pre-eclampsia has been observed to transiently decrease
blood pressure [4]. Assuming low aldosterone avail-
ability to be the cause rather than the consequence of
pre-eclampsia [5], we recently observed an association
between a reduced 18-methyl oxidase, the rate limiting
enzymatic step of aldosterone synthase (CYP11B2), an
increased frequency of polymorphisms in the gene of
the same enzyme and pre-eclampsia [6]. Likewise,
patients with inborn corticosterone methyl oxidase
deﬁciency are known to decompensate at times of
sodium deprivation. Here, we demonstrate for the ﬁrst
time the utility of prescribing supplemental NaCl for a
woman with neither the increase in aldosterone
production nor the blood pressure drop expected
during pregnancy.
Case report
A 33-year-old woman had received a diagnosis of
essential arterial hypertension 15 years ago. Renin
activity was normal. She was followed at the
Department of Nephrology and Hypertension of the
University of Berne. Her blood pressure was well-
controllable by dual antihypertensive treatment
(calcium channel and b-blocker) at 123 and 84mmHg
systolic and diastolic, respectively, during the 6 month
period prior to conception. Throughout pregnancy,
ofﬁce blood pressure readings were taken at twice-
weekly scheduled follow-up visits using the ﬁrst
and ﬁfth Korotkoff sound and according to current
guidelines. Ofﬁce blood pressure measurements were
supplemented by three home self-measurements per day
performed by the patient herself using an automated
device, which had been calibrated and controlled at our
clinic. Blood pressure recordings were collected using
the patient’s blood pressure diary and our outpatient’s
clinics ﬁles. Weekly means were derived from the daily
averages of typically three independent measurements.
At ﬁve weeks of gestation in her ﬁrst pregnancy, the
patient stopped all antihypertensive drugs. The average
blood pressure increased to 132 and 87mmHg systolic
and diastolic, respectively, and remained within this
unusual ﬁrst trimester range for the consecutive weeks
(Figure 1). Twenty-four hour urinary samples were
analysed by gas chromatography–mass spectroscopy
for urinary steroid metabolites, as described earlier [6].
High ratios indicate low enzyme activities. In normal
pregnancy, tetrahydroaldosterone excretion increases,
indicating a high aldosterone production. In the patient
presented, tetrahydroaldosterone excretion remained
low compared with normal pregnant women (Table 1).
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We observed absence of the expected increase in
aldosterone synthase activity in pregnancy as indicated
by the following ratios [6]: deoxycorticosterone to
tetrahydroaldosterone and total deoxycorticosterone
to tetrahydroaldosterone (both reﬂecting all enzymatic
steps of aldosterone synthase activity) and of
18-hydroxy-precursors of aldosterone, denoted by
18-hydroxy-tetrahydro-11-dehydrocorticosterone to
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Fig. 1. Systolic and diastolic blood pressure is presented. Pre-gestational blood pressure is the mean±SEM of monthly ofﬁce cuff
measurements during six proceeding months. Gestational blood pressure is presented as weekly mean±SEM of triplicate daily measurements
veriﬁed by ofﬁce measurements every other week. After delivery, daily means±SEM of three to ﬁve measurements are given. The
NaCl supplementation is indicated at the bottom. Total (supplemental and dietary) NaCl uptake as calculated from urinary 24 h Naþ
excretion in g/day.
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tetrahydroaldosterone (reﬂecting 18-methyl oxidase
activity) (Table 2). Compared with regular pregnancies,
this led to an 11.9-fold raised ratio of
18-hydroxy-tetrahydro-11-dehydrocorticosterone to
tetrahydroaldosterone pointing towards a metabolic
defect at the level of 18-methyl oxidase activity
(Table 2). In contrast to non-pregnant urinary steroid
hormone metabolites assessed 3 years ago, the missing
switch to pregnancy-induced hyperaldosteronism is
most prominent in these three ratios. The analysis of
urinary steroid metabolites indicated no abnormalities
with respect to the activity of 11b-hydroxysteroid
dehydrogenase or 11b-hydroxylase (Table 2). Genetic
analysis of the CYP11B2 revealed homozygocity for
a loss-of-function mutation as observed earlier by
our group [6]. Given the hypoaldosteronism, sodium
supplementation aiming at 20 g total NaCl intake
per day as deﬁned by the 24 h urinary sodium excretion
was initiated and pursued throughout pregnancy
(Figure 1). Mean systolic and diastolic blood pressure
decreased by 16 and 12mmHg, respectively throughout
pregnancy, with just a limited increase not reaching
initial values prior to delivery (Figure 1). Due to breech
presentation, delivery was by primary caesarian section.
The child had a normal birth weight of 2800 g at
37 weeks of gestation. After delivery, the maternal
blood pressure rose to 165 and 105mmHg systolic and
diastolic, respectively. The NaCl supplementation
was terminated and b-blockade reinstalled.
Discussion
Treatment of hypertension in pregnancy and
prevention of pre-eclampsia by drugs and dietary
manoeuvres are issues still unsatisfyingly approached
in clinical practice. The blood pressure of the patient
presented did not fall in early pregnancy, in contrast
to the response expected in normal pregnancy even in
women with chronic hypertension [7]. Interestingly,
blood pressure was responsive to NaCl supplementa-
tion. This ﬁnding is in line with the hypothesis that
intravascular volume depletion causes increased blood
pressure in pregnancy. In a series reported recently
by us and in the patient presented here, an inadequate
increase in aldosterone production due to a
Table 2. Calculated ratios of steroid hormone urinary metabolites
Calculated ratios Non-pregnant Pregnant
KC Normal values as
reported in [6]
KC Normal values as
reported in [6]
11b-hydroxylase activity
[tetrahydro-11-deoxycortisol/(THEþTHFþ 5aTHF)] 100 1.38 (1.12±0.12) 2.20 (7.50±1.52)
(THDOC/(THEþTHFþ 5aTHF)) 100 0.26 (0.2±0.1) 31.1 (12.8±4.3)
11b-hydroxysteroid dehydrogenase activity
THB/THA 1.79 (1.30±0.10) 1.46 (0.94±0.17)
Aldosterone synthase activity
DOC/18-OH-THA 0.04 (0.27±0.07) 0.30 (1.01±0.55)
(THDOCþDOC)/18-OH-THA 0.40 (0.5±0.1) 18.1 (17.2±6.3)
(THAþTHBþ 5aTHB)/(THEþTHFþ 5aTHF) 0.10 (0.11±0.01) 0.06 (0.28±0.04)
DOC/THAldo 0.00 (0.23±0.07) 1.63 (0.15±0.07)
(THDOCþDOC)/THAldo 0.40 (0.44±0.07) 97.1 (4.04±1.06)
18-OH-THA/THAldo 9.48 (2.26±0.51) 5.37 (0.45±0.09)
Normal values are given as mean±SEM as reported in [6].
Table 1. Summary of analysis of steroid hormone urinary metabolites
Urinary ratios of steroid/creatinine (mg/mmol) Non-pregnant Pregnant
Index
patient
Normal values as
reported in [6]
Index
patient
Normal values as
reported in [6]
Tetrahydrocortisone (THE) 154 (201±29) 465 (507±62)
Tetrahydrocortisol (THF) 76 (103±15) 175 (196±62)
5a-tetrahydrocortisol (5aTHF) 29.4 (63.1±11.3) 45.1 (49.4±11.7)
Deoxycorticosterone (DOC) 0.0 (0.8±0.2) 3.7 (2.3±0.92)
(THDOCþDOC) 0.7 (1.5±0.3) 217 (63.5±14.7)
18-Hydroxy-tetrahydro-11-dehydrocorticosterone (18-OH-THA) 16.3 (7.0±2.4) 12.0 (13.7±3.9)
Tetrahydroaldosterone (THAldo) 1.7 (4.1±0.6) 2.2 (37.9±12.8)
THA 6.1 (8.2±1.3) 9.4 (47.7±8.1)
Tetrahydrocorticosterone (THB) 10.9 (10.8±2.1) 13.7 (38.5±8.3)
5aTHB 9.3 (19.8±3.1) 17.0 (27.5±3.0)
Normal values are given as mean±SEM as reported in [6].
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compromised aldosterone synthase activity was
observed in pregnancy [6].
Aldosterone is produced by the aldosterone synthase,
which comprises three enzymatic steps, the 11b- and
18-hydroxylation as well as the 18-methyl oxidation.
The aldosterone synthase is 93% homologous to the
11b-hydroxylase, an enzyme, which has limited
18-hydroxylation activity, and which is unable to
catalyse the last and rate limiting enzymatic step of
aldosterone production, the 18-methyl oxidation.
The absence of the expected increased aldosterone
synthesis during pregnancy in this patient was asso-
ciated with a homozygous, non-conservative mutation
of the aldosterone synthase gene, V386A, similar to our
earlier ﬁndings in a signiﬁcant number of pre-eclamptic
patients [6]. This mutation represents the sequence
normally present in CYP11B1 at a site of CYP11B2
heterologous to this enzyme, potentially an ancestral
gene conversion, and led in vitro to a reduced efﬁciency
to produce aldosterone [6–8].
The presence of persistent hypoaldosteronism
and reports emphasizing NaCl supplementation in
corticosterone methyl oxidase deﬁciency led us to
supplement salt in this woman. This salt supplementa-
tion was associated with a reduced blood pressure
throughout the pregnancy. Support for a critical role
of NaCl intake in pregnancy is provided by an early
observation by Robinson, who found a reduced
incidence of pre-eclampsia in pregnant women on
a high salt diet [9]. In this early study, a reduced risk
of developing pre-eclampsia by consuming 20 g/day
dietary NaCl was observed. The quasi randomized
design introduced substantial potential for bias in this
and two further studies performed 40 years ago on the
utility of a high salt diet in pregnancy [10]. Two studies
on low salt vs normal salt diet in pregnancy to prevent
pre-eclampsia including 603 patients indicated an
unchanged relative risk of developing pre-eclampsia
[10]. These data suggest that salt restriction during
pregnancy does not seem promising for the prevention
of pre-eclampsia and that a large number of women
would need to be randomized to detect a moderate to
small beneﬁcial effect. In summary, there is uncertainty
with respect to the utility of salt intake during
pregnancy. The report presented here indicates that
pregnant women with even subtle signs of volume
deﬁciency, probably in part attributable to a reduced
capacity to produce aldosterone, might beneﬁt from
salt supplementation in pregnancy.
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